Further, that administration of this B7- H3-directed cytotoxic agent could enhance tumor cell death and drive “auto-vaccination” of the host immune system, with added engagement of a T-cell response by sequenced administration of MGC018 in combination with anti-PD-1 antibody (MGA012; also known as INCMGA00012). Here, RPL17 is linked to neoplasm.